ESMO Colloquia - Past Meetings

Meeting resources from the ESMO Colloquia can be viewed by ESMO members and non-members on OncologyPRO: the home of ESMO’s educational and scientific resources.

Past Events

ELCC 2019

 

Resources from ESMO Colloquium  (ESMO Members only)

Wednesday, 10 April 2019

ESMO Colloquium - How to Best Use Immune Checkpoint Inhibitors in NSCLC: Single Agents or Combined With Chemotherapy?

How to Best Use Immune Checkpoint Inhibitors In NSCLC: Single Agents or Combined With Chemotherapy? Thumb

Room A, 11:45 – 13:15
This educational activity is provided by ESMO and supported by Lilly in collaboration with MSD.
View the ESMO Colloquium details

Learning Objectives

  • Review the optimal immunotherapy options for NSCLC in first line
  • Discuss the rationale for combining Immune Check Points (ICPs) among themselves or with cytotoxic drugs
  • Evaluate the role of anti-angiogenics in combination with Chemotherapy and ICPs treatment
ESMO Asia Congress 2018

 

Resources from ESMO Colloquium (ESMO Members Only)

Friday, 23 November 2018

ESMO Colloquium: Immunotherapy of lung cancer:  Alone or in combination?

Immunotherapy of Lung Cancer: Alone or in Combination? Thumbnail

Room 311, 12:45-14:15
This educational activity is provided by ESMO and supported by Lilly and Roche.
View the ESMO Colloquium details

Learning Objectives

  • Review the optimal immunotherapy options for NSCLC in 1st line
  • Discuss the rationale for combining immune checkpoints (ICPs) among themselves or with cytotoxic drugs
  • Evaluate the role of anti-angiogenics in combination with chemotherapy and ICPs
  • Acquire knowledge of recent Guidelines on 1st line NSCLC with ICP treatment

Friday, 23 November 2018

ESMO Colloquium: Oncology biosimilars in Asia

Oncology Biosimilars in Asia Thumbnail

Hall 404, 16:30-18:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO Colloquium details

Learning Objectives

  • Understand the state of play, in the Asia- Pacific community, concerning the development and uptake of oncology biosimilars (moAbs)
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars emerging from the recent survey conducted by ESMO
  • Discuss the example of India, a country producing biosimilars in the region
  • Assess the financial impact of oncology biosimilars on healthcare systems within the APAC region

Saturday, 24 November 2018

ESMO Colloquium: Updated therapeutic approach of castration-resistant prostate cancer (CRPC)

Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) Thumbnail

Room 324, 12:45-14:15
This educational activity is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives

  • To review the peculiar aspects of CRPC
  • To evaluate the benefit of conventional chemotherapy in CRPC
  • To understand the impact of androgen receptor inhibition in CRPC
  • To get an update of potential development in immunotherapy of CRPC

Sunday, 25 November 2018

ESMO Colloquium: Metastatic gastric and oesophago-gastric cancers

Metastatic Gastric and Oesophagogastric Cancers Thumbnail

Room 324, 9:15-10:15
This educational activity is provided by ESMO and supported by Lilly.
View the ESMO Colloquium details

Learning Objectives

Review the optimal treatment options in 1st line according to the biomarker profile

  • Discuss treatment of patients fit for 2nd line, selection criteria, nutritional status impact
  • Learn about recent results of immunotherapy for metastatic gastric cancer
  • Acquire knowledge of recent Guidelines
ESMO Congress 2018

 

Resources from ESMO Colloquium  (ESMO Members only)

Saturday, 20 October 2018

ESMO Colloquium: Hepatocellular carcinoma (HCC) treatment: Now, next and beyond

Hepatocellular carcinoma treatment thumb

Room: ICM – Room 1, 13:00-14:30
This educational activity is provided by ESMO and supported by Eisai.
View the ESMO colloquium details

Learning Objectives

  • To enhance understanding of loco-regional therapy (LRT) options and the evidence base to support the optimal outcomes
  • To inspire debate regarding what the optimal transition is from LRT to first line systemic treatment for HCC
  • To present the first line systemic treatment options and the rationale to move beyond monotherapy in a first line setting

Saturday, 20 October 2018

ESMO Colloquium: Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines

Systemic therapies in unresectable hepatocellular carcinoma thumb

Room: ICM – Room 14B, 18:30-20:00
This educational activity is provided by ESMO and supported by IPSEN.
View the ESMO colloquium details

Learning Objectives

  • To better understand the biology of HCC and the potential targets to be used
  • To review the efficacy of targeted agents in unresectable HCC
  • To get an update on the present potential role of immune checkpoints inhibitors
  • To overview the possible future treatment strategies with new agents or combined modalities

Sunday, 21 October 2018

ESMO Colloquium: Immune checkpoint inhibitors: Are we ready for combination?

Immune checkpoint inhibitors thumb

Room: Hall B3 – Room 22, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives

  • To look at different ways of combining immune checkpoints inhibitors with same or different classes of treatment
  • To consider the potential adverse events
  • To review the present data in lung and breast cancer
  • To understand the role of potential predictive factors
  • To put in perspective the magnitude of clinical benefit compared to other alternatives

Sunday, 21 October 2018

ESMO Colloquium: Acute myeloid leukaemia: Focus on FLT3-ITD mutation

Acute myeloid leukaemia thumb

Room: Hall A1 – Room 15, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo.
View the ESMO colloquium details

Learning Objectives

  • To dissect acute myeloid leukemias from a molecular alteration point of view
  • To put the present molecular characterization in perspective with guidelines
  • To address the specificities of FTL3-ITD mutated subtype
  • To review the present achievements with the use of molecular targeted approaches

Sunday, 21 October 2018

ESMO Colloquium: Are Biosimilars the key to access, in practice?

Are Biosimilars the key to access thumb

Room: Hall A1– Room 16, 18:30-20:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO colloquium details

Learning Objectives

  • Build confidence around the use of biosimilars in oncology, by providing examples of existing biosimilar use in supportive care (eg. Growth factors & epoetins)
  • Understand the concerns patients may have while getting switched from an originator to a biosimilar
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars following the recent survey conducted by ESMO about modulating the efficacy of immunotherapy
  • Assess the financial impact of oncology biosimilars on healthcare systems